U.S. Launch of Novo's New Insulin Faces Long Delay

01.05.2013 - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said...